Norgine and European Liver Patients Association (ELPA) Continuing to Improve the Management of Hepatic Encephalopathy
LONDON, England, - Norgine and ELPA have launched a patient leaflet to improve the early detection of hepatic encephalopathy, and a patient passport to facilitate conversations with healthcare professionals. Hepatic encephalopathy remains under-diagnosed and under-treated, as many patients and carers are unaware of the signs and symptoms of the disease. In addition, healthcare providers don't always identify and treat the often subtle symptoms of hepatic encephalopathy, and this can lead to poor patient outcomes and increased hospital admissions.
Hepatic encephalopathy is a significant complication of advanced chronic liver disease, and occurs in up to 40% of patients or as many as 200,000 people in Europe.
Tatjana Reic, President, ELPA said "In Europe, 200,000 people are affected by hepatic encephalopathy, yet despite the severity of the disease it is still under-diagnosed and under-treated. The new patient leaflet and passport are welcome as they will help patients and their carers to manage this debilitating disease which can significantly impact people's lives and those who care for them."
Peter Martin, Chief Operating Officer, Norgine said "Norgine is highly committed to working with ELPA so together we can ensure that hepatic encephalopathy is recognised as a life threatening condition and that patients can be managed accordingly."
Click here to download Patient Passport
Understanding Hepatic Encephalopathy patient leaflet, patient passport and Time to DeLiver report are sponsored by Norgine.
View the full press release on http://www.norgine.com
Livia Alimena, Public Affairs Director
Norgine media contacts
Isabelle Jouin, T: +44-(0)1895-453643
Charlotte Andrews, T: +44-(0)1895-453607
Follow us @Norgine